VYNE Therapeutics Inc. (VYNE)
Jul 27, 2026 - VYNE was delisted (reason: merged with YARW)
28.56
+3.11 (12.22%)
Inactive · Last trade price on Jul 27, 2026
VYNE Therapeutics Employees
VYNE Therapeutics had 10 employees as of December 31, 2025. The number of employees decreased by 3 or -23.08% compared to the previous year.
Employees
10
Change (1Y)
-3
Growth (1Y)
-23.08%
Revenue / Employee
$45,400
Profits / Employee
-$2,145,700
Market Cap
19.05M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 10 | -3 | -23.08% | 10 | 0 |
| Dec 31, 2024 | 13 | 3 | 30.00% | 13 | 0 |
| Dec 31, 2023 | 10 | -2 | -16.67% | 10 | 0 |
| Dec 31, 2022 | 12 | -16 | -57.14% | 12 | 0 |
| Sep 30, 2022 | 28 | 0 | - | 28 | 0 |
| Jun 30, 2022 | 28 | - | - | 28 | 0 |
| Mar 31, 2022 | 28 | -78 | -73.58% | 28 | 0 |
| Dec 31, 2021 | 28 | -78 | -73.58% | 28 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
VYNE News
- 5 days ago - Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves' Disease and Thyroid Eye Disease - Business Wire
- 9 days ago - VYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow Bioscience - GlobeNewsWire
- 11 days ago - VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow Bioscience - GlobeNewsWire
- 18 days ago - VYNE Therapeutics Slides: Investor presentation - Filings
- 22 days ago - VYNE Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Yarrow Bioscience - GlobeNewsWire
- 2 months ago - VYNE Therapeutics Quarterly report: Q1 2026 - Filings
- 5 months ago - VYNE Therapeutics Annual report: Q4 2025 - Filings
- 8 months ago - VYNE Therapeutics Transcript: M&A Announcement - Transcripts